Melissa Bradbury Lobato Instituciones de las que forman parte Investigación Biomédica en Ginecología Vall Hebron Institut de Recerca Médico Ginecologia Oncològica i Patologia del Tracte Genital Inferior Hospital Infantil i Hospital de la Mujer Email Melissa Bradbury Lobato Email Instituciones de las que forman parte Investigación Biomédica en Ginecología Vall Hebron Institut de Recerca Médico Ginecologia Oncològica i Patologia del Tracte Genital Inferior Hospital Infantil i Hospital de la Mujer
Líneas de investigación Ovarian Cancer Research Research team: Dr. Melissa Bardbury (Principal researcher) Dr. Antonio Gil-Moreno (Principal researcher) Dra. Anna Santamaría (Stable collaborator) Dr. Eva Coll (PhD student) Dr. Carlos López (PhD student) Dr. Melek Denizli (Technician) Dr. José Luís Sánchez Iglesias (Clinical associated investigator) Dr. Armando Reques (Clinical associated investigator) Dr. Assumpció Pérez-Benavente (Clinical associated investigator) Dr. Vicente Bebia Conesa (Clinical associated investigator) Dr. Natalia Rodríguez Gómez-Hidalgo (Clinical associated investigator) Dr. Javier de la Torre Fernández de Vega (Clinical associated investigator) Research focus PERIOPERATIVE IMMUNOMODULATION IN OVARIAN CANCER Surgery for advanced ovarian cancer is a stressful stimulus that results in a pro-catabolic hormonal and cytokine environment, which significantly impacts metabolism. This metabolic response is accompanied by immune system impairment, increasing the risk of post-operative complications. In this research line the group is working in a multidisplinary project within the ERAS® program at the Vall d’Hebron Hospital for the: Identification of inflammatory markers predicting improved recovery after surgery within an ERAS® protocol. MOLECULAR DIAGNOSTICS AND PREDICTION OF TREATMENT RESPONSE IN OVARIAN CANCER Ovarian cancer remains the leading cause of death from gynecological malignancies due to its late diagnosis and high recurrence rates following treatment. There is a need to improve the early detection of the disease and identify predictive markers of treatment response. These diagnostic and predictive markers are being identified in proximal body fluids and patient-tissue samples. In this research line, the group has 3 ongoing projects: Proteomic biomarkers for an improved diagnosis in uterine aspirates and pap-smears. Proteomic biomarkers for the prediction of treatment response. SalivOmiX: A salivary miRNA-based test for ovarian cancer early diagnosis. IP: Melissa Bradbury Lobato, Antonio Gil Moreno Preinvasive and invasive disease of the lower genital tract research Research team: Dr. Melissa Bradbury (Principal researcher) Dr. Cristina Centeno (Clinical associated investigator) Dr. Antonio Gil-Moreno (Principal researcher) Dr. Carme Dinarés (Clinical associated investigator) Dr. Josep Castellví (Clinical associated investigator) Dr. Armando Reques (Clinical associated investigator) Dr. Angel Garcia (Clinical associated investigator) Dra. Eva Colás (Translational associated researcher) Dr. Melek Denizli (Technician) Research focus NEW MARKERS FOR THE DIAGNOSIS AND PROGRESSION OF INTRAEPITHELIAL NEOPLASIA OF THE LOWER GENITAL TRACT Persistent infections with high-risk human papillomavirus (HPV) genotypes are necessary, but not sufficient, cause of preinvasive and invasive lesions of the cervix and the lower genital tract. Although cancer screening prevention is based on HPV screening and pap-smear tests, it is essential to identify new molecular markers that can predict the transformation of HPV-associated lesions. In this research line our group is assessing: Identification of molecular markers associated to an increased risk of development, persistence and progression of preinvasive lesions of the lower genital tract. IP: Melissa Bradbury Lobato Proyectos Recerca biomèdica en ginecologia IP: Antonio Gil Moreno Colaboradores: Natalia Rodriguez Gómez - Hidalgo, Elena Suarez Salvador, Jose Luis Poza Barrasus, Vicente Bebia Conesa, Angel García Jiménez, Maria Asuncion Perez Benavente, Carina Masferrer Ferragutcasas, Eva Colas Ortega, Sabina Salicrú Riera, Anna Ruano Lopez, Fco Javier De la Torre Fdez de Vega, Montserrat Cubo Abert, Silvia Cabrera Diaz, Laura Mañalich Barrachina, Marta Rebull Santamaria, Mireia Armengol Alsina, Ana Luzarraga Aznar, Irene De la Calle Fuentes, José Luis Sánchez Iglesias, Melissa Bradbury Lobato, Beatriz Villafranca Magdalena, Melek Denizli Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 40000 Referencia: 2021 SGR 01157 Duración: 01/01/2022 - 30/06/2025 Targeting the most aggressive type of endometrial carcinoma IP: Antonio Gil Moreno Colaboradores: Carina Masferrer Ferragutcasas, Marta Rebull Santamaria, Irene De la Calle Fuentes, Beatriz Villafranca Magdalena, Melek Denizli, Melissa Bradbury Lobato, Raquel Delgado Gil Entidad financiadora: Asociación Española Contra el Cáncer Financiación: 199250 Referencia: GCTRA18014MATI Duración: 18/02/2019 - 31/10/2024 SalivOmiX: Test basado en el análisis de miRNAS en saliva para la detección precoz de cáncer de ovario. IP: Anna Santamaria Margalef Colaboradores: Maria Asuncion Perez Benavente, José Luis Sánchez Iglesias, Melissa Bradbury Lobato Entidad financiadora: Instituto de Salud Carlos III Financiación: 159720 Referencia: PI18/01017 Duración: 01/01/2019 - 30/06/2023 Sol·licitud Melissa. IP: Anna Santamaria Margalef Colaboradores: Melissa Bradbury Lobato, Miriam Izquierdo Sans Entidad financiadora: Fundació Institut de Recerca HUVH Financiación: 107196 Referencia: PHD4MD/04/BRADBURY/2016 Duración: 01/10/2016 - 30/09/2019
